Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being done to compare the effects, good and bad, of fractionated CO2 laser treatment and clobetasol propionate .05% ointment on vulvar lichen sclerosus.
Vulvar lichen sclerosus (LS) is a well-characterized dermatosis resulting in labial atrophy, synechiae and introital narrowing and can often cause dyspareunia, itching and co-existent vulvar pain. Biopsy is necessary to confirm the clinical diagnosis and the mainstay of treatment usually consists of topical steroid therapy (Chi). Clobetasol propionate and mometasone furoate are potent topical steroids that have long been considered gold-standard treatment for vulvar lichen sclerosus and work through anti-inflammatory, anti-mitotic, and immunosuppressive effects. One of the complications of long-term steroid use, however, is potential thinning of the vulvar skin, therefore limiting long-term use. Clobetasol propionate has a range of efficacy from 61-91% depending on the selected outcome criteria.
The vulvovaginal SmartXide -V2-LR laser system by DEKA (Calezano, Italy) is a fractionated C02 laser with maximum 40 Watt power and laser energy emission at 10,600 nanometer wavelength which is mainly absorbed by water in the underlying tissue (Salvatore). The SmartXide-V2-LR system was first introduced in 2009 with DOT therapy distributing fractioned CO2 laser in small spots of 200 microns to the vulvar skin or vaginal epithelium, resulting in a portion of the skin remaining intact with less tissue destruction and faster healing (Salvatore). The device is cleared by the US Food and Drug Administration (FDA) for incision, excision, ablation, and coagulation of gynecologic soft tissues. The fractioned therapy has been shown to stimulate fibroblastic growth through activation and biosynthesis of collagen and restoration of the extracellular matrix with collagen fibers.
Very little is known about long-term effects of fractionated C02 laser therapy use in the vulva or vagina, although the treatment is widely accepted in plastic and cosmetic surgery and dermatology. Increased marketing for laser vaginal rejuvenation has spawned a proprietary female genital cosmetic surgery industry in the US with very limited published outcome data. SmartXide -V2-LR has some established outcome data for treatment of genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy (Salvatore).
The purpose of this study is to compare the safety and efficacy of clobetasol propionate .05% ointment to fractionated CO2 laser procedure for the treatment of vulvar lichen sclerosus. Women presenting to the urogynecology clinic will be screened for lichen sclerosus. Vulvar biopsy will be performed for confirmation, and, if eligible, the patient will be consented to undergo baseline questionnaires, photodocumentation of vulvar lesions and randomization. A minimum of 2 weeks are required from the time of biopsy to treatment. Patient will be randomized to monthly LASER treatment for 3 months or topical STEROID therapy (clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) in a 1:1 ratio using a computer generated randomization schedule. Because of the nature of the treatment, it will not be possible to blind patients but the assessor will be blinded to the intervention. Patients may have used clobetasol propionate in past, but must complete 8 week wash out period.
Patient questionnaires include multiple validated scales and surveys to provided reproducible measures of vulvar symptoms as primary and secondary outcomes. Questionnaires will be completed at the intake visit, repeated at 6 month and one year follow up. The investigators expect improved subjective and objective results in the LASER group at 6 months compared with the STEROID group. At 6 months, participants are giving the option to crossover to receive the other treatment arm if desired due to continued symptoms. All groups are followed to 12 months for comparison.
Sample size calculations were conducted using the absolute change in the Skindex 29 as the primary end point. Out study will reach 80% power to detect a mean difference of 16 points on the Skindex 29 (sd=22 for both groups) between the study groups with 25 patients in each group, or 50 in total based on a one-sided two-sample t-test with alpha=0.05 (He). By accounting for 10% attrition, the investigators propose to recruit 56 patients to the study to be randomized with a 1:1 ratio to each group, with a blocked component for those who used tropical clobetasol in the past.
Data will be entered into a secure RedCAPS Database which provides complete auditing for data management processes. De-identified backup data will be kept in locked files at the participating site. Plans for publication will be handled by the investigators at MedStar Washington Hospital Center and will adhere to publication policies. All personnel with access to data collected have completed the Program for Ethics Education in Research training with the appropriate HIPAA certification.
Patients will not be compensated for travel and may be accountable for some medical bills for office visits. Study location is Medstar Lafayette Office 1133 21st St NW, Washington, DC 20036.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prior Clobetasol Exposure | Experimental | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate |
|
| No Prior Clobetasol Exposure | Active Comparator | Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fractionated Carbon Dioxide Laser | Device | Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in SkinDEX-29 Score | The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement in symptoms (better outcome). | Change from baseline score to score at six months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ) | Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement. | Baseline to six months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cheryl Iglesia, MD | Medstar Health Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medstar Washington Hospital Center Lafayette Office | Washington D.C. | District of Columbia | 20010 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22161424 | Background | Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD008240. doi: 10.1002/14651858.CD008240.pub2. | |
| 24605832 | Background | Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014 Aug;17(4):363-9. doi: 10.3109/13697137.2014.899347. Epub 2014 Jun 5. |
Not provided
Not provided
Not provided
Patients were recruited from urogynecologic and gynecology academic center office visits with vulvar biopsy-proven lichen sclerosus. Patients underwent block randomization with a 1:1 ratios, with stratification for participants based on prior clobetasol use. Participates stayed in randomized group until six months when they had the option to crossover into other treatment group and receive that treatment or continue to 12 months with current treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Clobetasol Propionate- No Crossover | Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment then as need. Participants did not cross over. |
| FG001 | Fractionated Carbon Dioxide Laser- No Crossover | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. Then no further treatment. |
| FG002 | Clobetasol Propionate to Laser Crossover | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment then as need. Participants choose to crossover to Fractionated Carbon Dioxide Laser at six months because symptoms had not resolved. Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. |
| FG003 | Fractionated Carbon Dioxide Laser to Clobetasol Crossover | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. Then patients choose to crossover to the Clobetasol Propionate Treatment at six months due to continued symptoms. Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment then as need. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Six Month Follow Up |
|
| ||||||||||||||||||
| One Year Follow Up |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fractionated Carbon Dioxide Laser | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in SkinDEX-29 Score | The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement in symptoms (better outcome). | Posted | Mean | Standard Deviation | score on a scale | Change from baseline score to score at six months |
|
Adverse events were collected at 12 weeks, six months, and one year post treatment
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Clobetasol Propionate- 0-6 Months | Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment then as need. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| minor burning and blistering at treatment site | Reproductive system and breast disorders | Systematic Assessment | adverse event was minor burning and blistering at laser site |
The study was unblinded for patients and evaluators and only performed at a single center. The steroid group had more non-compliant patients (25% vs 4%). We limited our investigation to only postmenopausal women Further research using placebo and sham lasers for treatment blinding is needed. Patients previously using topical vaginal estrogen were continued on prior treatment, groups were not stratified based on estrogen exposure, however there where equal numbers between groups.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Cheryl Iglesia | Medstar Health Research Institute | 202-877-6526 | cheryl.iglesia@medstar.net |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 15, 2015 | Jul 14, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Apr 4, 2018 | Jul 16, 2021 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D007724 | Vulvar Lichen Sclerosus |
| D018459 | Lichen Sclerosus et Atrophicus |
| D056650 | Vulvodynia |
| ID | Term |
|---|---|
| D014845 | Vulvar Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D002990 | Clobetasol |
| D009824 | Ointments |
| ID | Term |
|---|---|
| D001623 | Betamethasone |
| D013259 | Steroids, Fluorinated |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Clobetasol Propionate 0.05% ointment | Drug | Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment. |
|
|
| Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ) | Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement. | Six month to one year after treatment |
| Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score | Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction. | Six months from treatment |
| Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score | Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction. | 1 year from treatment |
| Change Vaginal Health Index (VHI) Score | The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points. | Baseline to 6 months after treatment |
| Change Vaginal Health Index (VHI) Score | The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points. | Six month to one year after treatment |
| Change Vulvar Symptom Visual Analog Scale (VAS) Score | Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Baseline to 6 months after treatment |
| Change Vulvar Symptom Visual Analog Scale (VAS) Score | Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement in symptoms (better outcome). | Six months to one year after treatment |
| Change SkinDEX-29 Score | The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement. | Six months to one year from treatment |
| Change Objective Provider VAS Visual Analog Scale | Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Baseline to Six months from treatment |
| Change Objective Provider VAS Visual Analog Scale | Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Six months to One Year from treatment |
| Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment | Six Month to One Year from treatment |
| Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment. | 12 Weeks to Six months from treatment |
| Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment. | 12 Weeks from treatment |
| 25539748 | Background | He Z, Lu C, Chren MM, Zhang Z, Li Y, Ni X, Buchtel V HA, Ryan PF, Li GZ. Development and psychometric validation of the Chinese version of Skindex-29 and Skindex-16. Health Qual Life Outcomes. 2014 Dec 24;12:190. doi: 10.1186/s12955-014-0190-4. |
| 33957642 | Derived | Burkett LS, Siddique M, Zeymo A, Brunn EA, Gutman RE, Park AJ, Iglesia CB. Clobetasol Compared With Fractionated Carbon Dioxide Laser for Lichen Sclerosus: A Randomized Controlled Trial. Obstet Gynecol. 2021 Jun 1;137(6):968-978. doi: 10.1097/AOG.0000000000004332. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| BG001 | Clobetasol Propionate | Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Prior Clobetasol Exposure | Count of Participants | Participants |
|
| OG001 | Clobetasol Propionate | Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment |
|
|
|
| Secondary | Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ) | Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Baseline to six months |
|
|
|
|
| Secondary | Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ) | Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Six month to one year after treatment |
|
|
|
| Secondary | Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score | Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction. | Posted | Count of Participants | Participants | Six months from treatment |
|
|
|
|
| Secondary | Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score | Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction. | Posted | Count of Participants | Participants | 1 year from treatment |
|
|
|
| Secondary | Change Vaginal Health Index (VHI) Score | The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points. | Posted | Mean | Standard Deviation | score on a scale | Baseline to 6 months after treatment |
|
|
|
|
| Secondary | Change Vaginal Health Index (VHI) Score | The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points. | Posted | Mean | Standard Deviation | score on a scale | Six month to one year after treatment |
|
|
|
| Secondary | Change Vulvar Symptom Visual Analog Scale (VAS) Score | Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Baseline to 6 months after treatment |
|
|
|
| Secondary | Change Vulvar Symptom Visual Analog Scale (VAS) Score | Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement in symptoms (better outcome). | Posted | Mean | Standard Deviation | score on a scale | Six months to one year after treatment |
|
|
|
| Secondary | Change SkinDEX-29 Score | The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Six months to one year from treatment |
|
|
|
| Secondary | Change Objective Provider VAS Visual Analog Scale | Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Baseline to Six months from treatment |
|
|
|
| Secondary | Change Objective Provider VAS Visual Analog Scale | Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement. | Posted | Mean | Standard Deviation | score on a scale | Six months to One Year from treatment |
|
|
|
| Secondary | Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment | Posted | Count of Participants | Participants | Six Month to One Year from treatment |
|
|
|
| Secondary | Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment. | Posted | Count of Participants | Participants | 12 Weeks to Six months from treatment |
|
|
|
| Secondary | Number of Patients With Adverse Outcomes | Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment. | Please see adverse events section for description of adverse events. | Posted | Count of Participants | Participants | 12 Weeks from treatment |
|
|
|
| 0 |
| 27 |
| 0 |
| 27 |
| 1 |
| 27 |
| EG001 | Fractionated Carbon Dioxide Laser- 0-6 Months | Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. | 0 | 24 | 0 | 24 | 1 | 24 |
| EG002 | Clobetasol Propionate to Laser Crossover 6-12 Months | Participants previously in the Clobetasol Propionate 0.05% ointment group. Participants choose to crossover to Fractionated Carbon Dioxide Laser at six months because symptoms had not resolved. Fractionated Carbon Dioxide Laser: Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart. | 0 | 11 | 0 | 11 | 0 | 11 |
| EG003 | Fractionated Carbon Dioxide Laser to Clobetasol Crossover 6-12 Months | Participants previously in the Fractionated Carbon Dioxide Laser group choose to crossover to the Clobetasol Propionate Treatment at six months due to continued symptoms. Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment then as need. | 0 | 10 | 0 | 10 | 0 | 10 |
| EG004 | Clobetasol Propionate - No Crossover 6-12 Months | Clobetasol Propionate 0.05% ointment Topical Steroid therapy (Clobetasol propionate .05% ointment continued as need. No Crossover. | 0 | 11 | 0 | 11 | 0 | 11 |
| EG005 | Fractionated Carbon Dioxide Laser- No Crossover 6-12 Months | Participants previoulsly treated with Fractionated Carbon Dioxide Laser choose to not undergo any further treatment. | 0 | 16 | 0 | 16 | 0 | 16 |
|
| Activation Genital Herpes | Reproductive system and breast disorders | Systematic Assessment | adverse event was activation of genital herpes one week after starting steroid |
|
Not provided
Not provided
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D017512 | Lichenoid Eruptions |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D011083 |
| Polycyclic Compounds |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
| Irritation |
|
| Pain with sex |
|
| Tearing of vulvar skin |
|
| Dysuria |
|
| Pain defecation |
|
| Burning |
|
| Irritation or tearing |
|
| Pain with sex |
|
| Tearing of vulvar skin |
|
| Dysuria |
|
| Painful defecation |
|
| Introital Narrowing |
|
| Perianal Involvement |
|
| Loss of Labial Minora |
|
| Fusion of Labia Minora |
|
| Phimosis |
|
| Fissure |
|
| Erosion |
|
| Cigarette Paper |
|
| Introital Narrowing |
|
| Perianal Involvement |
|
| Loss of Labial Minora |
|
| Fusion of Labia Minora |
|
| Phimosis |
|
| Fissure |
|
| Erosion |
|